Mark Harvey
Corporate Officer/Principal presso The University of Queensland
Posizioni attive di Mark Harvey
Società | Posizione | Inizio | Fine |
---|---|---|---|
The University of Queensland | Corporate Officer/Principal | - | - |
Storia della carriera di Mark Harvey
Precedenti posizioni note di Mark Harvey
Società | Posizione | Inizio | Fine |
---|---|---|---|
CM Capital Investments Pty Ltd.
CM Capital Investments Pty Ltd. Investment ManagersFinance CM Capital Investments Pty Ltd is a venture capital firm, a subsidiary of Talu Ventures Pty Ltd founded in 1998 by Michael Begun and Carmel J. Hillyard, The firm is headquartered in Brisbane. | Director of Investments | 01/04/2006 | 20/11/2012 |
Investitore di Private Equity | 01/04/2006 | 20/11/2012 | |
NUWELLIS, INC. | Direttore/Membro del Consiglio | 03/10/2011 | 12/11/2012 |
Independent Dir/Board Member | 29/03/2012 | 12/11/2012 | |
OSPY MEDI CDI | Direttore/Membro del Consiglio | 01/06/2011 | - |
Symbiosis Group Ltd.
Symbiosis Group Ltd. Investment ManagersFinance Symbiosis Group Ltd. (Symbiosis) is a venture capital subsidiary of UniQuest Pty Ltd. founded in 2004.The firm headquartered in Queensland, Australia. | Investitore di Private Equity | - | 01/04/2006 |
Pathway Therapeutics, Inc.
Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | - | - |
ANU Connect Ventures Pty Ltd.
ANU Connect Ventures Pty Ltd. Investment ManagersFinance ANU Connect Ventures Pty Ltd (ANU Connect Ventures) is a venture capital subsidiary of Australian National University founded in 2005. The firm is headquartered in Canberra, Australia. | Membro del Comitato di Investimento | 19/05/2011 | - |
Investitore di Private Equity | 19/05/2011 | - | |
Pathway Therapeutics Ltd.
Pathway Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Pathway Therapeutics Ltd. developed drugs for the treatment of cancer. The company was founded in 2007 and was headquartered in Auckland, New Zealand. | Direttore/Membro del Consiglio | 01/07/2010 | - |
Formazione di Mark Harvey
The University of Queensland | Doctorate Degree |
Statistiche
Distribuzione geografica
Australia | 5 |
Stati Uniti | 4 |
Nuova-Zelanda | 2 |
Posizioni
Director/Board Member | 4 |
Private Equity Investor | 3 |
Director of Investments | 1 |
Settori
Health Technology | 5 |
Finance | 4 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
NUWELLIS, INC. | Health Technology |
Aziende private | 6 |
---|---|
Pathway Therapeutics, Inc.
Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Health Technology |
CM Capital Investments Pty Ltd.
CM Capital Investments Pty Ltd. Investment ManagersFinance CM Capital Investments Pty Ltd is a venture capital firm, a subsidiary of Talu Ventures Pty Ltd founded in 1998 by Michael Begun and Carmel J. Hillyard, The firm is headquartered in Brisbane. | Finance |
Pathway Therapeutics Ltd.
Pathway Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Pathway Therapeutics Ltd. developed drugs for the treatment of cancer. The company was founded in 2007 and was headquartered in Auckland, New Zealand. | Health Technology |
Osprey Medical, Inc.
Osprey Medical, Inc. Medical SpecialtiesHealth Technology Osprey Medical, Inc. engages in the development to prevent harmful effect of x-ray dye used during angiographic imaging procedures. Its product includes Dyevert system, which is designed to reduce the amount of dye contrast injected into the patients during standard cardiovascular procedures. The company was founded by Frank Solomon, David Kaye, and James Edward Shapland on August 31, 2005 and is headquartered in Minnetonka, MN. | Health Technology |
ANU Connect Ventures Pty Ltd.
ANU Connect Ventures Pty Ltd. Investment ManagersFinance ANU Connect Ventures Pty Ltd (ANU Connect Ventures) is a venture capital subsidiary of Australian National University founded in 2005. The firm is headquartered in Canberra, Australia. | Finance |
Symbiosis Group Ltd.
Symbiosis Group Ltd. Investment ManagersFinance Symbiosis Group Ltd. (Symbiosis) is a venture capital subsidiary of UniQuest Pty Ltd. founded in 2004.The firm headquartered in Queensland, Australia. | Finance |
- Borsa valori
- Insiders
- Mark Harvey
- Esperienza